Invesco
OTLK icon

Invesco’s Outlook Therapeutics OTLK Stock Holding History

Invesco’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,009
Closed -$15.8K – 3920
2023
Q4 		$15.8K Sell
2,009
-517
-20% -$4.37K ﹤0.01% 3808
2023
Q3 		$11.2K Hold
2,526
– – ﹤0.01% 3865
2023
Q2 		$87.9K Buy
2,526
+150
+6% +$4.09K ﹤0.01% 3751
2023
Q1 		$51.8K Buy
2,376
+394
+20% +$8.81K ﹤0.01% 3756
2022
Q4 		$42.8K Sell
1,982
-254
-11% -$5.53K ﹤0.01% 3920
2022
Q3 		$55K Buy
2,236
+309
+16% +$7.18K ﹤0.01% 3910
2022
Q2 		$39K Buy
1,927
+400
+26% +$11.5K ﹤0.01% 4005
2022
Q1 		$54K Sell
1,527
-10
-0.7% -$312 ﹤0.01% 3923
2021
Q4 		$42K Sell
1,537
-30
-2% -$1.07K ﹤0.01% 3995
2021
Q3 		$68K Buy
1,567
+394
+34% +$19K ﹤0.01% 3982
2021
Q2 		$58K Buy
+1,173
New +$54.4K ﹤0.01% 3942

Other funds holding OTLK

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Invesco's OTLK Position: Q1 2024 in Review

Invesco sold out of Outlook Therapeutics (OTLK) in Q1 2024, closing a stake of 2,009 shares — an estimated $15.8K sold.

Invesco first reported a position in OTLK in Q2 2021 and held it in 11 quarters. The position peaked at $87.9K in Q2 2023. 56 funds tracked by Wall St. Rank hold OTLK as of Q1 2024.

  • Invesco reported no remaining Outlook Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Invesco sold 2,009 Outlook Therapeutics shares in Q1 2024, an estimated $15.8K.
  • Invesco first reported a position in Outlook Therapeutics in Q2 2021 and held it in 11 quarters.
  • Invesco's Outlook Therapeutics position peaked at $87.9K in Q2 2023.
  • 56 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2024.

Based on Invesco's 13F filing for Q1 2024, filed 14 May 2024.